Mesoblast Limited has reported its financial results for the fiscal year ending June 30, 2025. The company recorded a net loss of $102.1 million for the year, compared to a net loss of $87.956 million in the prior year, marking a 16% increase in losses. The accumulated losses as of June 30, 2025, stand at $1.0109 billion. The biotechnology company continues to face significant losses since its inception and anticipates that these losses may persist for the foreseeable future. Mesoblast Limited is primarily engaged in the research and clinical development of its product candidates, with increased attention from health regulators on product safety and treatment efficacy contributing to rising research and development expenses. The company's management has implemented a cost containment strategy, which included a decrease in consulting expenses by $1.2 million and recruitment costs by $0.2 million for the year ended June 30, 2024, compared to the previous year. Additionally, there was a reduction in overall salary and associated expenses by $0.4 million due to a decrease in full-time equivalents. Mesoblast Limited remains focused on continuing its research and clinical development efforts, expecting future capital requirements to continue as it advances its product candidates.